Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Common Equity of -$1.4 million for Q4 2025, down 13.37% sequentially from -$1.3 million in Q3 2025, and down 93.13% YoY from -$20.8 million in Q4 2024.
Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Common Equity for 6 years, with the latest figure at -$1.4 million in Q4 2025.
- Quarterly Common Equity fell 93.13% year-over-year to -$1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.4 million (down 93.13% YoY) and the FY2025 annual result came in at -$1.4 million, down 93.13% from the prior year.
- Common Equity slipped to -$1.4 million in Q4 2025 per RAPH's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Common Equity peaked at $191000.0 in Q2 2021 and troughed at -$1.4 million in Q4 2025.
- A 5-year average of -$305350.0 and a median of -$89000.0 in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity jumped 397.67% in 2021, then plunged 1044.44% in 2024.
- Over 5 years, Common Equity stood at $128000.0 in 2021, then declined by 17.19% to $106000.0 in 2022, then grew by 0.94% to $107000.0 in 2023, then sank by 793.46% to -$742000.0 in 2024, then tumbled by 93.13% to -$1.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$1.4 million, -$1.3 million, and -$1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.26 Mn |
| Jun 30, 2025 | -1.05 Mn |
| Mar 31, 2025 | -734,000.00 |
| Dec 31, 2024 | -742,000.00 |
| Sep 30, 2024 | -616,000.00 |
| Jun 30, 2024 | -290,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Mar 31, 2023 | -9,000.00 |
| Dec 31, 2022 | 106,000.00 |
| Sep 30, 2022 | -62,000.00 |
| Jun 30, 2022 | 118,000.00 |
| Mar 31, 2022 | 103,000.00 |
| Dec 31, 2021 | 128,000.00 |
| Sep 30, 2021 | -125,000.00 |
| Jun 30, 2021 | 191,000.00 |
| Mar 31, 2021 | -298,000.00 |